In an interview recorded during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020, Luciano Costa, MD, PhD, of UAB School of Medicine, Birmingham, AL, discusses recent data on BCMA-targeted approaches in multiple myeloma, including chimeric antigen receptor (CAR) T-cell therapies, antibody-drug conjugates, and bispecific T-cell engagers. Dr Costa also discusses three phase 1 trials in relapsed/refractory multiple myeloma designed to investigate the bispecific antibody talquetamab, which binds GPRC5D and CD3, the bispecific T-cell engager BFCR4350A, and the BCMA-targeting bispecific antibody therapy teclistamab. Dr Costa notes that this meeting represents the next chapter in the immunotherapy revolution in multiple myeloma.